Watt S M, Forde S P
Stem Cells and Immunotherapies, NHS Blood and Transplant, John Radcliffe Hospital, Headington, Oxford, UK and Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
Vox Sang. 2008 Jan;94(1):18-32. doi: 10.1111/j.1423-0410.2007.00995.x. Epub 2007 Nov 27.
Recent clinical trials have used CXCR4 antagonists for the rapid mobilization of CD34(+) haemopoietic stem/progenitor cells (HSC/HPC) from the bone marrow to the blood in patients refractory to granulocyte-colony-stimulating factor (G-CSF). These antagonists not only mobilize non-cycling cells with a higher proportion of repopulating cells, but also enhance CD34(+) cell mobilization when used in combination with G-CSF. Here, we review the importance of CXCR4 and its ligand CXCL12 in haemopoiesis, and the potential roles of CXCR4 antagonists in the clinical HSC transplant setting.
近期的临床试验使用CXCR4拮抗剂，以便在对粒细胞集落刺激因子（G-CSF）难治的患者中，将CD34(+)造血干细胞/祖细胞（HSC/HPC）从骨髓快速动员至血液中。这些拮抗剂不仅能动员具有更高比例再增殖细胞的非循环细胞，而且与G-CSF联合使用时还能增强CD34(+)细胞的动员。在此，我们综述CXCR4及其配体CXCL12在造血过程中的重要性，以及CXCR4拮抗剂在临床造血干细胞移植中的潜在作用。
